Cargando…

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy

PURPOSE: Despite the success of chimeric antigen receptor (CAR) T cells in clinical studies, a significant proportion of responding patients eventually relapsed, with the latter correlating with low CAR T cell expansion and persistence. METHODS AND RESULTS: Using patient-derived xenograft (PDX) mous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ning, Tse, Benjamin, Yang, Lu, Tang, Tiffany C Y, Haber, Michelle, Micklethwaite, Kenneth, Dolnikov, Alla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091475/ https://www.ncbi.nlm.nih.gov/pubmed/33954150 http://dx.doi.org/10.2147/ITT.S296161

Ejemplares similares

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Characterizing piggyBat—a transposase for genetic modification of T cells
por: Sutrave, Gaurav, et al.
Publicado: (2022)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
por: Ebelt, Nancy D., et al.
Publicado: (2022)

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

Effects of 5-Azacytidine on Growth and Hypocrellin Production of Shiraia bambusicola
por: Ma, Yan Jun, et al.
Publicado: (2018)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Suppressing nonsense—a surprising function for 5-azacytidine
por: Shao, Ada, et al.
Publicado: (2014)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

DNA methyltransferase inhibitor 5-azacytidine enhances neuroblastoma cell lysis by an oncolytic parainfluenza virus
por: Kedarinath, Kritika, et al.
Publicado: (2023)

5-Azacytidine Enhances the Radiosensitivity of CNE2 and SUNE1 Cells In Vitro and In Vivo Possibly by Altering DNA Methylation
por: Jiang, Wei, et al.
Publicado: (2014)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia
por: Cheng, Jason X., et al.
Publicado: (2018)

5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
por: Ebelt, Nancy D., et al.
Publicado: (2020)

5-Azacytidine Is Insufficient For Cardiogenesis In Human Adipose-Derived Stem Cells
por: Wan Safwani, Wan Kamarul Zaman, et al.
Publicado: (2012)

A Comparative Analysis of 5-Azacytidine- and Zebularine-Induced DNA Demethylation
por: Griffin, Patrick T., et al.
Publicado: (2016)

Effect of the Addition Frequency of 5-Azacytidine in Both Micro- and Macroscale Cultures
por: Kadekar, Sandeep, et al.
Publicado: (2020)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Wang, Yanyu, et al.
Publicado: (2022)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
por: Gu, Xiaorong, et al.
Publicado: (2020)

5-Azacytidine and Resveratrol Enhance Chondrogenic Differentiation of Metabolic Syndrome-Derived Mesenchymal Stem Cells by Modulating Autophagy
por: Marycz, K., et al.
Publicado: (2019)

Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia
por: Cheng, Jason X., et al.
Publicado: (2018)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Retracted: Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

DNA methylation patterns of Brachypodium distachyon chromosomes and their alteration by 5-azacytidine treatment
por: Borowska, Natalia, et al.
Publicado: (2011)

5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion
por: Bhuvanagiri, Madhuri, et al.
Publicado: (2014)

How to Diagnose Early 5-Azacytidine-Induced Pneumonitis: A Case Report
por: Misra, Srimanta Chandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gfj1v9gu4tofn3effci45gcu9k